In accordance with Senate Bill 486, codified within Public Resources Code, Chapter 1 of Part 7 of Division 30, Sections 47115-47116, and Laws of Minnesota 2010, Chapter 286, Senate File No. 1323, Pfizer is pleased to submit this report, which describes the Company’s current sharps disposal support provided to patients who self-inject Pfizer medicines at home, and our plans for next year.

As background for public readers of this report, the California Legislature passed and the Governor signed SB 486 in October 2009. The bill requires, on or before July 1, 2010, and annually thereafter, pharmaceutical manufacturers that sell or distribute medication that is self-injected at home through the use of hypodermic needles and other similar devices (i.e., sharps) to submit to CalRecycle a plan that describes how the manufacturer supports the safe collection and proper disposal of the used sharps.

The Minnesota legislation signed by the Governor (April 30, 2010) also requires qualifying companies to post to their websites how they support the safe collection and proper disposal of sharps. As such, this report is posted to www.pfizer.com/ehs.

HIGHLIGHTS

• Pfizer provides information to patients for one-on-one instruction for all its self-injecting patients for all its self-injected products, nationwide.

• Pfizer provides information to patients to help them understand how to safely dispose of their injection devices, and the state and local requirements for sharps disposal, nationwide.

• Patients have multiple options to get sharps disposal questions answered, and get assistance in finding a local disposal option nationwide.

• Pfizer is innovating, by offering safer injection devices or reducing the number of sharps needed to administer its medicines.

• Pfizer supports the Coalition for Community Safe Needle Disposal, and its efforts to ensure patients can find the latest information on local, regional, and state sharps disposal programs.

(cont. on next page)
Pfizer’s Safe Sharps Disposal Plan (cont)

Pfizer has nine products that are approved for self-injection by patients in the home. Five of the products are biopharmaceuticals (BeneFix, Enbrel, Genotropin, Somavert, and Xyntha) that are provided to patients through specialty pharmacies, which are specially equipped to store and ship the medicines to patients properly (often they are refrigerated or frozen). One product, (Alsuma) is currently marketed in the US only. The remaining three products are older products that are or will soon face generic competition (Caverject and Neumega), and a Pfizer-generic product (Epinephrine Injection, USP).

GENERAL SHARPS MANAGEMENT
It is Pfizer’s policy to customize our support uniquely to the characteristics of each product and the needs of its patients; therefore, the sharps disposal support will likely differ product by product. However, the following general provisions apply throughout the portfolio.

In 2011 Pfizer worked closely with its industry peers to produce a consistent and appropriate approach to sharps disposal.

PROVIDER, PATIENT AND USER EDUCATION
Doctors, nurse trainers, call center staff and patients have access to www.safeneedledisposal.org via Pfizer’s product stewardship website. This site has an up-to-date summary of state sharps disposal requirements, with links to state programs.

All users of injectable medicines for home use are given advice and guidance on the safe disposal of used and expired medicines by trained health care providers when they receive their medicines.

All product inserts advice the patient to dispose of sharps in a responsible and appropriate manner in line with the guidance as provided by the health care provider.

Pfizer provides product-specific toll free patient support numbers that give additional support and guidance around sharps disposal. Information can also be found on Pfizer’s Product Stewardship website.
Pfizer’s Safe Sharps Disposal Plan (cont)

PRODUCT PROGRAMS & INNOVATION
Pfizer is working towards providing a comprehensive sharps management and disposal program. Aligned with this aim are a number of products that already have specific initiatives and technologies in place. During 2012 work is underway to build upon these efforts.

ALSUMA™
The Alsuma™ Auto-Injector is supplied with a number of features that assist in the safe use and disposal of this treatment.

• Each Auto-Injector is provided to the patient with an individual storage and disposal case designed to prevent damage to the injector and inadvertent contact.

• The injector itself is designed with a retractable needle which further prevents inadvertent contact with the needle.

ENBREL®
Enbrel is offered in a single-use, SureClick auto-injector that can be considered a safe needle device because the needle retracts into the device after use. Additionally patients may enroll in a sharps mail back program. Patients receive a 1 gallon sharps container with a pre-paid shipping container, additional containers are sent to patients prior to mailing the full container back.

SHARPS DISPOSAL SUPPORT PLANS FOR 2012 -2013
The majority of Pfizer medicines that are self-injected at home reach patients through specialty pharmacies, which are specially equipped to store and ship the biopharmaceutical medicines properly to patients. Pfizer has reached out to several pharmacy trade associations in the hope of finding a means of reaching, on a national basis, this subset of patient pharmacies.

The product inserts associated with Pfizer’s self-injected products currently provide correct and detailed sharps disposal instructions. However, the language is not consistent between all products and devices.

The product inserts associated with Pfizer’s self-injected products currently provide accurate and detailed sharps disposal instructions. Over time, as product insets are updated, Pfizer is planning to revise the sharps disposal language in all product inserts to ensure consistent messaging.

For any questions regarding this report, please contact Pfizer’s Product Stewardship lead at 1-212-733-7356.